Æterna Zentaris Inc.

Find Ratings Reports
AEZS : NASDAQ : Health Technology
$1.65 -0.04 | -2.37%
Today's Range: 1.631 - 1.7005
Avg. Daily Volume: 692700.0
03/19/18 - 4:00 PM ET

Financial Analysis

AETERNA ZENTARIS INC's gross profit margin for the third quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Sales and net income have dropped, although the growth in revenues underperformed the average competitor within the industry, the net income growth did not. AETERNA ZENTARIS INC is extremely liquid. Currently, the Quick Ratio is 2.23 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 159.56% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.

Income Statement Q3 FY17 Q3 FY16
Net Sales ($mil)0.240.27
EBITDA ($mil)0.0-7.67
EBIT ($mil)-4.09-7.7
Net Income ($mil)-9.63-6.06

Balance Sheet Q3 FY17 Q3 FY16
Cash & Equiv. ($mil)12.1721.05
Total Assets ($mil)22.5431.74
Total Debt ($mil)0.00.0
Equity ($mil)-1.963.28

Profitability Q3 FY17 Q3 FY16
Gross Profit Margin-1695.02-2852.04
EBITDA Margin0.0-2852.04
Operating Margin-1695.02-2863.57
Sales Turnover0.050.02
Return on Assets-108.84-84.3
Return on Equity0.0-816.02
Debt Q3 FY17 Q3 FY16
Current Ratio2.323.98
Interest Expense0.00.0
Interest Coverage0.00.0

Share Data Q3 FY17 Q3 FY16
Shares outstanding (mil)16.4410.09
Div / share0.00.0
Book value / share-0.120.33
Institutional Own % n/a n/a
Avg Daily Volume695895.0422021.0


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
AEZS NM Peers 47.18   AEZS NM Peers 25.10

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

AEZS's P/E is negative making this valuation measure meaningless.


Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

AEZS's P/CF is negative making the measure meaningless.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
AEZS NA Peers 25.68   AEZS NA Peers 0.38

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.


Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
AEZS NM Peers 20.65   AEZS 42.54 Peers -0.73

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

AEZS's P/B is negative making this valuation measure meaningless.


Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

AEZS is expected to have an earnings growth rate that significantly exceeds its peers.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
AEZS 26.31 Peers 78.78   AEZS 47.95 Peers 472.09

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

AEZS is trading at a significant discount to its industry on this measurement.


Lower. A sales growth rate that trails the industry implies that a company is losing market share.

AEZS significantly trails its peers on the basis of sales growth



Latest Stock Upgrades/Downgrades